← Leaderboards
Xiaolei Zhu
Johns Hopkins University
$2,447,865
Attributed
$2,447,865
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,447,865 · 3
By mechanism
R56$1,104,325 · 1
K01$675,675 · 1
R01$667,865 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Barbara Stauch Slusher$18,499,514
- Atsushi Kamiya$7,560,680
- Christine Lee Vigeland$966,986
- Jonathan D Powell$15,512,358
- Eric Hutton Raabe$804,830
Others in their field
Other Emerging Leaders on “Functional Disorder”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- Susan M Landau · University Of California Berkeley$47,252,026
- Evan Z Macosko · Broad Institute, Inc.$28,495,187
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
- Barbara Halina Braffett · George Washington University$22,016,904
Research focus
Functional DisorderPhenotypeNeuroinflammationPathologicInflammatoryInflammationMouse ModelPlayRodent ModelMental DepressionBehavior TestSocialData SetBehaviorMajor Depressive DisorderPathway InteractionsNeuropsychiatric DisorderComorbidityInflammatory MarkerMediating3-DimensionalHiv InfectionsAntiretroviral TherapyInfection
Grant awards (8)
The role of microglial glutaminase in HIV-induced sleep deficits$667,865
R01 · FY2025 · HL · contact PI
Microglia-targeted glutaminase inhibition forthe treatment of chronic stress-associated depression$578,134
R56 · FY2025 · MH · contact PI
Microglia-targeted glutaminase inhibition forthe treatment of chronic stress-associated depression$526,191
R56 · FY2024 · MH · contact PI
Exploring a natural product to modulate aberrant gut bacterial-fungal interactions as pathological mechanisms underlying HIV-associated depression$135,135
K01 · FY2024 · AT · contact PI
Exploring a natural product to modulate aberrant gut bacterial-fungal interactions as pathological mechanisms underlying HIV-associated depression$135,135
K01 · FY2023 · AT · contact PI
Exploring a natural product to modulate aberrant gut bacterial-fungal interactions as pathological mechanisms underlying HIV-associated depression$135,135
K01 · FY2022 · AT · contact PI
Exploring a natural product to modulate aberrant gut bacterial-fungal interactions as pathological mechanisms underlying HIV-associated depression$135,135
K01 · FY2021 · AT · contact PI
Exploring a natural product to modulate aberrant gut bacterial-fungal interactions as pathological mechanisms underlying HIV-associated depression$135,135
K01 · FY2020 · AT · contact PI